Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Neutrophil percentage-to-albumin ratio is a potential marker of intravenous immunoglobulin resistance in Kawasaki disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      Mucocutaneous Lymph Node Syndrome*/blood ; Mucocutaneous Lymph Node Syndrome*/drug therapy ; Immunoglobulins, Intravenous*/therapeutic use ; Neutrophils* ; Drug Resistance* ; Biomarkers*/blood; Humans ; Male ; Female ; Child, Preschool ; Infant ; Retrospective Studies ; Child ; Albumins/metabolism
    • نبذة مختصرة :
      Intravenous immunoglobulin (IVIG) resistance in Kawasaki disease (KD) was associated with coronary artery lesions. Neutrophil percentage-to-albumin ratio (NPAR) is an index of mortality in several inflammatory diseases. This study focused on the association of NPAR with IVIG- resistance in KD. Clinical and laboratory data of 438 children with KD before IVIG treatment were retrospectively analyzed. Notably, high NPAR was associated with older age, high WBC, NP, ALT, total bilirubin and CRP, as well as with high the incidence of IVIG-resistance, and with low hemoglobin (Hb), PLT, ALB and sodium levels. NPAR (OR: 2.366, 95% CI: 1.46-3.897, p = 0.001) and Hb (OR: 0.967, 95% CI: 0.944-0.989, p = 0.004) were independent risk factors for IVIG-resistance. NPAR showed linear relation with IVIG-resistance (p for nonlinear = 0.711) and the nonlinear correlation was found between IVIG-resistance and Hb (p for nonlinear = 0.002). The predictive performance of NPAR was superior to Beijing model (z = 2.193, p = 0.028), and not inferior to Chongqing model (z = 0.983, p = 0.326) and the combination of NPAR and Hb (z = 1.912, p = 0.056). These findings revealed that NPAR is a reliable predictor of IVIG-resistance.
      (© 2024. The Author(s).)
    • References:
      Front Neurol. 2021 Sep 08;12:705790. (PMID: 34566849)
      Arch Dis Child. 2019 Mar;104(3):262-267. (PMID: 30026252)
      Biomed Res Int. 2020 Feb 18;2020:5687672. (PMID: 32219136)
      BMC Cardiovasc Disord. 2022 Mar 18;22(1):115. (PMID: 35300600)
      Clin Rheumatol. 2021 Dec;40(12):5019-5024. (PMID: 34148165)
      Circulation. 2017 Apr 25;135(17):e927-e999. (PMID: 28356445)
      J Inflamm Res. 2023 Feb 18;16:691-700. (PMID: 36844255)
      Int J Mol Sci. 2017 Apr 12;18(4):. (PMID: 28417923)
      Clin Chim Acta. 2020 Aug;507:264-270. (PMID: 32387635)
      J Infect Dis. 1999 Feb;179(2):508-12. (PMID: 9878040)
      Epidemiol Infect. 2020 Apr 02;148:e87. (PMID: 32238212)
      Circulation. 2002 Feb 12;105(6):766-9. (PMID: 11839635)
      Heart Vessels. 2021 Sep;36(9):1366-1373. (PMID: 33686555)
      Ital J Pediatr. 2023 Jun 25;49(1):78. (PMID: 37357258)
      Circulation. 2006 Jun 6;113(22):2606-12. (PMID: 16735679)
      Sci Rep. 2019 Feb 11;9(1):1722. (PMID: 30742060)
      Int Immunopharmacol. 2023 Sep;122:110600. (PMID: 37423157)
      Pediatr Int. 2017 Jun;59(6):669-674. (PMID: 28097746)
      Circulation. 2004 Oct 26;110(17):2747-71. (PMID: 15505111)
      Ann Med. 2022 Dec;54(1):442-453. (PMID: 35099338)
      Int Immunopharmacol. 2020 Dec;89(Pt A):107037. (PMID: 33242833)
      Lancet. 2004 Aug 7-13;364(9433):533-44. (PMID: 15302199)
      Circulation. 2011 Dec 20;124(25):2822-8. (PMID: 22104548)
      Congenit Heart Dis. 2017 Sep;12(5):633-635. (PMID: 28580712)
      Int J Gen Med. 2022 Jan 04;15:1-9. (PMID: 35018109)
      Circulation. 2003 Jul 22;108(3):325-30. (PMID: 12835221)
      Rheumatol Int. 2019 Oct;39(10):1797-1801. (PMID: 31302740)
      Am J Med. 2020 Jun;133(6):713-722.e7. (PMID: 31751531)
      J Am Soc Echocardiogr. 2016 Aug;29(8):794-801.e29. (PMID: 27288089)
      Eur J Gastroenterol Hepatol. 2023 Feb 1;35(2):198-203. (PMID: 36472501)
      Biomed Res Int. 2020 Nov 26;2020:7458451. (PMID: 33294452)
    • Grant Information:
      2022YFS0627 Sichuan Science and Technology Program; 2023LZXNYDJ042 Luzhou Municipal People's Government-Southwest Medical University Science and Technology strategic cooperation
    • الرقم المعرف:
      0 (Immunoglobulins, Intravenous)
      0 (Biomarkers)
      0 (Albumins)
    • الموضوع:
      Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240725
    • الموضوع:
      20240726
    • الرقم المعرف:
      PMC11219825
    • الرقم المعرف:
      10.1038/s41598-024-66135-5
    • الرقم المعرف:
      38956281